Menu
Recruiting NCT07112924

CCM OPEN HF Registry

Observational Heart Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Heart Failure. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

CCM Technologies OPEN HF Registry: Observational Patient EvaluatioN of CCM® Therapy for Heart Failure

Overview

The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.

Detailed description

This is a global, prospective and retrospective, multicenter, single-arm, observational study intended to include patients who will receive/have received CCM therapy with an Impulse Dynamics system, including future CCM technologies (e.g. CCM-D), for a follow-up period of at least 5 years.

Primary outcome measures

  • Assess CCM's effect on the rate and length of stay of heart failure (HF) hospitalizations [Time frame: 1 Year]
  • Demonstrate the long-term safety of CCM therapy in a real-world setting, by assessing the rate of device- or procedure-related complications. [Time frame: 5 Years]
Secondary outcome measures (12)
  • Assess CCM's effect on clinical outcomes [Time frame: 5 Years]
  • Assess CCM's effect on mortality (all-cause, cardiovascular, and heart failure related) [Time frame: 5 Year]
  • Assess CCM's effect on healthy days at home (HDAH) [Time frame: 3 Years]
  • Assess CCM's effect on functional capacity [Time frame: 5 Year]
  • Kansas City Cardiomyopathy Questionnaire (KCCQ) [Time frame: 1 Year]
  • Assess CCM's effect cardiovascular reverse remodeling [Time frame: 5 Year]
  • Assess CCM's effect QRS duration [Time frame: 5 Years]
  • Assess CCM's systemic effects [Time frame: 5 Years]
  • Assess long-term CCM device-related adverse events and lead related events [Time frame: 5 Years]
  • Assess the dose response of CCM therapy [Time frame: 5 Year]
  • Evaluate subject battery charging compliance [Time frame: 5 Year]
  • Assess the effect of ancillary equipment on clinical outcomes [Time frame: 5 Years]

Eligibility criteria

Inclusion criteria

  • Patients who have /will be implanted with Impulse Dynamics CCM technologies (e.g. CCM or CCM-D when available) as determined by investigators
  • Willing and able to provide informed consent, including for use of data for research purposes (e.g. publication, sub-studies/sub-analyses)

Exclusion criteria

  • Noncompliant patients (e.g. for follow-up visits, medication, etc.) as determined by investigators.
  • Subjects with a mechanical tricuspid valve

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 28 centers
  • Cardiovascular Associates of Mesa — Mesa
  • University of Arizona and Banner University Medical Center Phoenix — Phoenix
  • HonorHealth Research Institute — Phoenix
  • Peak Heart and Vascular — Surprise
  • AdventHealth Orlando — Orlando
  • AdventHealth Tampa — Tampa
  • University of Kansas Medical Center — Kansas City
  • Massachusetts General Hospital — Boston
  • … and 20 more centers

Identifiers

NCT: NCT07112924 · OPEN_CA_CP_2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗